Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600458 | 1.00 | KEAP1 (0.58) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL9331674 | 1.00 | KEAP1 (0.58) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL4413196 | 1.00 | KEAP1 (0.58) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL29400837 | 0.96 | KEAP1 (0.57) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL30600462 | 0.96 | KEAP1 (0.57) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL4951645 | 0.94 | DPP8 (0.54) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL17073673 | 0.91 | KEAP1 (0.58) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL6281421 | 0.89 | DPP8 (0.59) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL25003569 | 0.88 | KEAP1 (0.56) | KEAP1NFE2L2DPP8DPP7SLC1A3 | |
| SCHEMBL18541545 | 0.87 | DPP8 (0.53) | KEAP1NFE2L2DPP8DPP7SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560227-B2 | Biomarkers of vulnerable atherosclerotic plaques and methods of use | UNIVERSITY OF MASSACHUSETTS (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070207507-A1 | Biomarkers of vulnerable atherosclerotic plaques and methods of use | UNIVERSITY OF MASSACHUSETTS (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2006093973-A2 | BIOMARKERS OF VULNERABLE A THEROSCLEROTIC PLAQUES AND METHODS OF USE | UNIVERSITY OF MASSACHUSETTS (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2005100382-A1 | VERTEBRATE PEPTIDE MODULATORS OF LIPID METABOLISM | BLM GROUP, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050222040-A1 | Vertebrate peptide modulators of lipid metabolism | BLM GROUP, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-5981580-A | IN WHICH THE CARBOXY-TERMINUS HAS BEEN MODIFIED TO FORM VARIOUS AMIDES, ESTERS, KETONES, ALCOHOLS, ALCOHOL ESTERS AND NITRITES THEREOF, AND ARE USEFUL AS SUBSTRATES FOR N-MYRISTOYLTRANSFERASE (NMT) AND/OR ITS ACYL COENZYME | G. D. SEARLE & CO. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5952377-A | SUBSTRATES FOR N-MYRISTOYLTRANSFERASE (NMT) AND/OR ITS ACYL COENZYME, AS ANTI-VIRAL AND ANTI-FUNGAL AGENTS OR PRO-DRUGS; TREATING AIDS, LENTIVIRUSES SUCH AS THE HUMAN IMMUNODEFICIENCY VIRUS | G. D. SEARLE & CO. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5929110-A | USEFUL AS SUBSTRATES FOR N-MYRISTOYLTRANSFERASE (NMT) AND/OR ITS ACYL COENZYME, AND AS ANTI-VIRAL AND ANTI-FUNGAL AGENTS OR PRO-DRUGS OF SUCH AGENTS | G. D. SEARLE & CO. (US) | 1999-07-27 | — | — | US | disclosed |
| US-5859052-A | TREATING LENTIVIRUS INFECTIONS, ESPECIALLY HUMAN IMMUNODEFICIENCY VIRUS | G. D. SEARLE & CO. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5744631-A | Fatty acid analogs and prodrugs | G.D. SEARLE & CO. (US) | 1998-04-28 | — | — | US | disclosed |
| US-5670650-A | ANTIVIRAL AND ANTIFUNGAL AGENTS | G. D. SEARLE & CO. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5599947-A | VIRICIDES, FUNGICIDES OR THEIR PRODRUGS | G. D. SEARLE & CO. (US) | 1997-02-04 | — | — | US | disclosed |
| US-5580953-A | USEFUL IN THERAPY OF TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE, OBESITY AND INSULIN RESISTANCE | AMYLIN PHARMACEUTICALS, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| US-4127531-A | ANALGESIC | VETERANS ADMINISTRATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY | 1978-11-28 | — | — | US | disclosed |
| US-4127538-A | ANALGESIC | VETERANS ADMINISTRATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY | 1978-11-28 | — | — | US | disclosed |
| US-4127526-A | ANALGESIC | VETERANS ADMINISTRATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY | 1978-11-28 | — | — | US | disclosed |
| US-4127533-A | ANALGESIC | VETERANS ADMINISTRATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY | 1978-11-28 | — | — | US | disclosed |
| US-4127537-A | ANALGESIC | VETERANS ADMINISTRATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY | 1978-11-28 | — | — | US | disclosed |
| US-4127522-A | ANALGESIC | VETERANS ADMINISTRATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY | 1978-11-28 | — | — | US | disclosed |
| US-3937695-A | P-Glu-Trp-Ser-Tyr-D-Lys-Leu-Arg-Pro-Gly-NH2 and intermediates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207507-A1 | Biomarkers of vulnerable atherosclerotic plaques and methods of use | CD68, APOB, FABP3 | KEAP1 4084/4885NFE2L2 4283/4885DPP8 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.